For the quarter ended March 2024, Abbott (ABT - Free Report) reported revenue of $9.96 billion, up 2.2% over the same period last year. EPS came in at $0.98, compared to $1.03 in the year-ago quarter.
The reported revenue represents a surprise of +1.15% over the Zacks Consensus Estimate of $9.85 billion. With the consensus EPS estimate being $0.96, the EPS surprise was +2.08%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Abbott performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net sales- Diagnostics- U.S. $931 million versus the three-analyst average estimate of $901.10 million. The reported number represents a year-over-year change of -30.3%.
- Net sales- Nutrition- International: $1.19 billion versus the three-analyst average estimate of $1.22 billion. The reported number represents a year-over-year change of +3%.
- Net sales- Nutrition- U.S. $878 million compared to the $884.13 million average estimate based on three analysts. The reported number represents a change of +8.1% year over year.
- Net sales- Diagnostics- International: $1.28 billion compared to the $1.26 billion average estimate based on three analysts. The reported number represents a change of -5.2% year over year.
- Net sales- Diagnostics: $2.21 billion versus $2.16 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -17.6% change.
- Net sales- Nutrition: $2.07 billion compared to the $2.10 billion average estimate based on four analysts. The reported number represents a change of +5.1% year over year.
- Net sales- Medical Devices- Diabetes Care: $1.57 billion versus the four-analyst average estimate of $1.54 billion. The reported number represents a year-over-year change of +19.5%.
- Net sales- Medical Devices: $4.45 billion versus $4.34 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +14.2% change.
- Net sales- Medical Devices- Neuromodulation- Total: $226 million versus $212.71 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +15.3% change.
- Net sales- Medical Devices- Structural Heart- Total: $515 million compared to the $502.18 million average estimate based on three analysts. The reported number represents a change of +11.7% year over year.
- Net sales- Medical Devices- Rhythm Management- Total: $562 million versus $547.02 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +6.6% change.
- Net sales- Medical Devices- Vascular- Total: $689 million compared to the $679.30 million average estimate based on three analysts. The reported number represents a change of +11.7% year over year.
View all Key Company Metrics for Abbott here>>>Shares of Abbott have returned -3.5% over the past month versus the Zacks S&P 500 composite's -1.1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Free Report – The Bitcoin Profit Phenomenon
Zacks Investment Research has released a Special Report to help you pursue massive profits from the world’s first and largest decentralized form of money.
No guarantees for the future, but in the past three presidential election years, Bitcoin’s returns were as follows: 2012 +272.4%, 2016 +161.1%, and 2020 +302.8%.
Zacks predicts another significant surge. Click below for Bitcoin: A Tumultuous Yet Resilient History.
Download Now – Today It’s FREE >>
For the quarter ended March 2024, Abbott (ABT - Free Report) reported revenue of $9.96 billion, up 2.2% over the same period last year. EPS came in at $0.98, compared to $1.03 in the year-ago quarter.
The reported revenue represents a surprise of +1.15% over the Zacks Consensus Estimate of $9.85 billion. With the consensus EPS estimate being $0.96, the EPS surprise was +2.08%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Abbott performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net sales- Diagnostics- U.S. $931 million versus the three-analyst average estimate of $901.10 million. The reported number represents a year-over-year change of -30.3%.
- Net sales- Nutrition- International: $1.19 billion versus the three-analyst average estimate of $1.22 billion. The reported number represents a year-over-year change of +3%.
- Net sales- Nutrition- U.S. $878 million compared to the $884.13 million average estimate based on three analysts. The reported number represents a change of +8.1% year over year.
- Net sales- Diagnostics- International: $1.28 billion compared to the $1.26 billion average estimate based on three analysts. The reported number represents a change of -5.2% year over year.
- Net sales- Diagnostics: $2.21 billion versus $2.16 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -17.6% change.
- Net sales- Nutrition: $2.07 billion compared to the $2.10 billion average estimate based on four analysts. The reported number represents a change of +5.1% year over year.
- Net sales- Medical Devices- Diabetes Care: $1.57 billion versus the four-analyst average estimate of $1.54 billion. The reported number represents a year-over-year change of +19.5%.
- Net sales- Medical Devices: $4.45 billion versus $4.34 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +14.2% change.
- Net sales- Medical Devices- Neuromodulation- Total: $226 million versus $212.71 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +15.3% change.
- Net sales- Medical Devices- Structural Heart- Total: $515 million compared to the $502.18 million average estimate based on three analysts. The reported number represents a change of +11.7% year over year.
- Net sales- Medical Devices- Rhythm Management- Total: $562 million versus $547.02 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +6.6% change.
- Net sales- Medical Devices- Vascular- Total: $689 million compared to the $679.30 million average estimate based on three analysts. The reported number represents a change of +11.7% year over year.
View all Key Company Metrics for Abbott here>>>Shares of Abbott have returned -3.5% over the past month versus the Zacks S&P 500 composite's -1.1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Free Report – The Bitcoin Profit Phenomenon
Zacks Investment Research has released a Special Report to help you pursue massive profits from the world’s first and largest decentralized form of money.
No guarantees for the future, but in the past three presidential election years, Bitcoin’s returns were as follows: 2012 +272.4%, 2016 +161.1%, and 2020 +302.8%.
Zacks predicts another significant surge. Click below for Bitcoin: A Tumultuous Yet Resilient History.
Download Now – Today It’s FREE >>
Get the latest research report on ABT - FREE